Home > Healthcare > Analytical Instruments > Lab Equipment and Supplies > CT/NG Testing Market

CT/NG Testing Market Size

Report ID: GMI9397
Published Date: May 2024
Report Format: PDF

Download Free Sample

CT/NG Testing Market Size

CT/NG Testing Market size was valued at USD 1.5 billion in 2023 and is anticipated to witness growth at a CAGR of 7.1% between 2024 and 2032, driven by the increasing incidence of sexually transmitted infections (STIs) coupled with growing awareness and screening programs.

CT/NG Testing Market

To get key market trends

Download Free Sample

There has been a global increase in the prevalence of sexually transmitted infections, including chlamydia (CT) and gonorrhea (NG). For instance, according to an article published by the World Health Organization in 2023, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic. Factors contributing to this rise include changes in sexual behavior, inadequate access to preventive measures, lack of STI education, and evolving patterns of STI transmission. As STI rates continue to escalate, there is a growing need for effective screening and diagnostic tools to detect and manage these infections promptly.

CT/NG Testing Market Report Attributes
Report Attribute	Details
Base Year:	2023
CT/NG Testing Market Size in 2023:	USD 1.5 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	7.1%
2032 Value Projection:	USD 2.8 Billion
Historical Data for:	2021 – 2023
No. of Pages:	110
Tables, Charts & Figures:	151
Segments covered:	Product Type, Test Type, Technology, End-use, and Region
Growth Drivers:	Increasing incidence of sexually transmitted infections (STIs) Growing awareness and screening programs Advancements in testing technologies
Pitfalls & Challenges:	Social stigma and under-reporting

Learn more about the key segments shaping this market

Download Free Sample

Moreover, increased awareness about the prevalence and risks associated with chlamydia (CT) and gonorrhea (NG) infections is driving public health campaigns aimed at educating individuals about the importance of STI screening. These campaigns, often conducted by government health agencies, non-profit organizations, and healthcare providers, raise awareness about the asymptomatic nature of these infections, their potential complications, and the importance of regular testing, especially among sexually active populations and high-risk groups. Therefore, the aforementioned factors drive the adoption of CT/NG testing devices among individuals and healthcare providers.

CT/NG testing refers to the diagnostic process used to detect the presence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections in individuals. These tests are performed on various specimen types, including urine, genital swabs, vaginal swabs, cervical swabs, urethral swabs, and rectal swabs, depending on the anatomical site of infection. CT/NG testing plays a crucial role in identifying and diagnosing these infections, allowing for prompt treatment and prevention of complications.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

CT/NG testing market size was USD 1.5 billion in 2023 and is expected to register 7.1% CAGR from 2024-2032 owing to the increasing incidence of sexually transmitted infections (STIs) coupled with growing awareness and screening programs worldwide.

CT/NG testing industry from the consumables segment held 74.9% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to offering convenient, all-in-one solutions for sample collection, processing, and detection.

North America CT/NG testing industry reached USD 533.4 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to advanced healthcare infrastructure, including well-equipped laboratories, healthcare facilities, and diagnostic centers in the region.

binx health, inc., Bioneer Corporation, Bio-Rad Laboratories, Inc., Cepheid, ELITech Group, Genetic Signatures, Hologic, Inc., Meridian Bioscience, Qiagen, Roche, Seegene, Inc., Thermo Fisher Scientific, Inc., and VIRCELL S.L., are some of the major CT/NG testing companies worldwide.